Rocket shares promising long-term results from rare heart disease gene therapy in small study

Rocket Pharmaceuticals reported Monday that benefits from its Danon disease gene therapy were seen up to around five years after treatment. The Cranbury, NJ-based biotech shared Phase 1 clinical trial results from seven patients who ...